STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease
Status:
NOT_YET_RECRUITING
Trial end date:
2030-05-15
Target enrollment:
Participant gender:
Summary
Autosomal dominant polycystic kidney disease is the most common genetic cause of kidney failure. The only approved treatment for ADPKD - tolvaptan - is limited in its use by massive therapy-associated polyuria. This trial tests if the SGLT2-inhibitor dapagliflozin slows down the loss of kidney function in ADPKD.